Article Text

Download PDFPDF
c-erbB-3 proto-oncogene expression in uterine cervical carcinoma
  1. C. R. Hunt*,
  2. R. J. Hale,
  3. C. Armstrong,
  4. T. Rajkumar§,
  5. W. J. Gullick§ and
  6. C. H. Buckley*
  1. * Department of Pathology, St Mary's Hospital, Manchester,
  2. Stepping Hill Hospital, Stockport,
  3. Bury General Hospital,
  4. § ICRF Oncology Unit, Hammersmith Hospital, London, UK
  1. Address for correspondence: Dr R. J. Hale, Department of Histopathology, Stockport Acute Services NHS Trust, Stepping Hill Hospital, Stockport, Cheshire SK2 7JE, UK.


Over-expression of epidermal growth factor receptor (EGFR) and c-erbB-2, in uterine cervical carcinomas, is associated with a worsened prognosis. A third member of this proto-oncogene family, c-erbB-3, has now been identified and its over-expression has been described in a variety of carcinomas. In this immunohistochemical study we have shown that c-erbB-3 is widely expressed in cervical carcinomas, but we have found no association between its over-expression and lymph node status or clinical outcome. In a similar study examining the expression of EGFR and c-erbB-2 it was possible to demonstrate an association between over-expression and a worse prognosis. We conclude, therefore, that it is unlikely that demonstration of c-erbB-3 over-expression will be of any value as a prognostic indicator in carcinoma of the uterine cervix.

  • cancer
  • c-erbB-3
  • cervix
  • immunohistochemistry prognosis.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.